Acadia is advancing breakthroughs in neuroscience to elevate life. For the past 30 years, we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. Acadia also has worldwide rights for the development and commercialization of trofinetide for Rett syndrome and other indications. Acadia is headquartered in San Diego, CA. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.